Feels like the later side of the sooner or later for a European partner… been a loong time since UK / European approvals.
But with the CEO and subsequent management shakeup, it moreso feels just about right, now-ish.
About that European partner, when?
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: About that European partner, when?
if they wanted a partner it would of been done by now - and should of been done by now - they are waiting for the interim analysis and hoping it is strong to make the final move
Re: About that European partner, when?
Yep, that’s been your opinion, and I respect it. I just don’t agree with that.
Geron is working to scale revenue now. Potential partners also want to make more money, now. A statement everyone can agree on for every single global biopharma…
MDS is an approved indication. It also, in whole not at the genetic biomarker level, is a larger patient population globally than MF. I am not sure about the contract inner workings but I can see a partner stepping in to start marketing and distributing Rytelo now, wirh escalators or whatever upon MF approval, which still seems far far off on the horizon to me (approval not initial data read, expected this year).
Geron is working to scale revenue now. Potential partners also want to make more money, now. A statement everyone can agree on for every single global biopharma…
MDS is an approved indication. It also, in whole not at the genetic biomarker level, is a larger patient population globally than MF. I am not sure about the contract inner workings but I can see a partner stepping in to start marketing and distributing Rytelo now, wirh escalators or whatever upon MF approval, which still seems far far off on the horizon to me (approval not initial data read, expected this year).